SHetA2 Therapy

SHetA2 Therapy Latest News

Recently, a new cervical cancer SHetA2 pill showed promise by stopping Human Papillomavirus (HPV) from turning cancerous. 

About SHetA2 Therapy

• SHetA2 is a small molecule therapy that is designed to stop an HPV infection from causing cancer.
• Small molecule therapies are chemically manufactured, low-weight compounds that can easily be absorbed by the body.
• It is designed to treat HPV-induced cervical dysplasia and cervical cancer.
• Working
  • This therapy targets three proteins in the human body called mortalin, heat shock cognate (hsc70), and glucose regulated protein 78 (Grp78).
  • These are essential for the proliferation of the cancer-causing oncoprotein of the virus.
  • It works by breaking the connection between the HPV-E7 protein and a host protein inside human cells.
  • Normally, this host protein protects E7 and allows it to keep damaging healthy cells. When SHetA2 breaks this connection, the harmful E7 protein is destroyed by the body’s normal immune defences.
• The therapy is meant for those who have developed precancerous lesions of cervical cancer.
• The therapy has, at present, been evaluated in an oral, capsule form. 

Key Facts about Human Papillomavirus (HPV)

• HPV is the most common sexually transmitted infection (STI), and there are more than 100 types of HPV.
• However, some types of HPV infection cause skin growths called warts, and some types of HPV infection can cause cancer.
• Transmission
  • The virus that causes HPV infection is transmitted through skin-to-skin contact. 
  • Most people get a genital HPV infection through direct sexual contact, including vaginal, anal, and oral sex.
  • About 80% of people – both men and women – will get an HPV infection at some point in their lives. 
• Symptoms may include warts on the genitals or anus or cancerous growths in the mouth or throat. 
• Treatment: There’s no cure for HPV. HPV vaccination is the most effective way to prevent HPV-related cancers.

Source: IE

‹ ›